Short Communication Open Access
Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/AIDS.3.023
Apigenin as Anti-TNF Alpha Agent
Tania Mulherkar1, Rashida Ginwala1, Zafar K. Khan1, Pooja Jai n1,*
- 1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19129, USA
Corresponding Author
Pooja Jain, pj27@drexel.com
Received Date: May 24, 2021
Accepted Date: October 19, 2021
Mulherkar T, Ginwala R, Khan ZK, Jain P. Apigenin as Anti-TNF Alpha Agent. J AIDS HIV Treat. 2021; 3(3): 49-53.
Copyright: © 2021 Mulherkar T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
TNF-alpha Inhibitors and Neutropenia: Current State of Art
To date, neutropenia and agranulocytosis related to TNF-α inhibitors have been discussed infrequently in the literature. In the current paper, a narrative review of the literature was performed on anti-TNF-α inhibitors, including infliximab, adalimumab, etanercept, golimumab, and certolizumab, using the PubMed database of the US National Library of Medicine. The review was restricted to autoimmune and auto-inflammatory diseases or other orphan diseases.
CD28 is Not Required for T cell Activation
It has been almost four decades since CD28 was identified as a major player (co-stimulator) of T cell activation and has been recognized as one of the major milestones in the T cell field. However, the exact underlying mechanism involved in the activation of CD28 still remains poorly understood. Most importantly, the depletion of CD28 in mice did not lead to a major defect in T cell activation response, even when combined with the deletion of ICOS, a homolog of CD28.